Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC

Exclusion Criteria

• •Participants who previously experienced active Ebola Virus Disease (EVD)
• •Receipt of any vaccine (licensed or experimental) within 30 days prior to recruitment
• •Receipt of an additional booster dose of either Ervebo®, Zabdeno®, or any experimental Ebola vaccine
• •Incorrect or incomplete primary vaccination scheme with the Zabdeno, Mvabea® (J\&J) vaccine
• •Administration of immunoglobulins and/or any blood products within three months prior to recruitment.
• •Fever (\>38°C) within last 24 hours prior to recruitment.
• •Any confirmed or suspected immunosuppressive or immunodeficient state (incl. cancer and HIV); asplenia; recurrent severe infections and use of immunosuppressant medication within the last 6 months, except topical or short-term oral steroids.
• •Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)
• •History of anaphylaxis, allergic disease or reactions to any component of the study vaccines
• •History of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture
• •History of any thrombotic disorder, thrombocytopenia, thrombotic thrombocytopenia syndrome (TTP), or heparin-induced thrombocytopenia and thrombosis (HITT)
• •Any other significant disease, disorder, planned surgery, or finding which may significantly affect the ability of the volunteer to participate in the study or impair interpretation of the study data
• •Suspected or known alcohol or drug dependency
• •Subject is not readily available by telephone, email or physical address
• •Agreement to refrain from blood donation and other vaccinations 30 days after study vaccination
• •Subjects who received either the Ervebo® vaccine, or the full Zabdeno, Mvabea® vaccine regimen more than 4 months prior to recruitment
• •Subjects who received either the Ervebo® vaccine or the full Zabdeno, Mvabea® vaccine regimen